XML 85 R67.htm IDEA: XBRL DOCUMENT
v3.24.0.1

FAIR VALUE - Narrative (Details) |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Feb. 22, 2024 USD ($) | Dec. 27, 2023 USD ($) | Dec. 12, 2023 USD ($) | Aug. 14, 2023 USD ($) intangibleAsset | Jul. 21, 2022 USD ($) intangibleAsset | Apr. 30, 2021 USD ($) intangibleAsset | Jun. 30, 2023 USD ($) intangibleAsset | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Nov. 19, 2021 USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Money Market Fund |  |  |  |  |  |  |  | $ 191,841,000 |  |  |
Payments on contingent consideration |  |  |  |  |  |  |  | 12,500,000 | $ 0 | $ 0 |
Intangible asset impairment charge |  |  |  |  |  |  |  | 0 | 112,000 | 2,374,000 |
Consideration |  |  |  |  |  |  |  | 9,643,000 | 7,579,000 | 21,081,000 |
Intangible assets acquired |  |  |  |  |  |  |  | 9,600,000 |  |  |
Finite-lived intangible gross carrying amount |  |  |  |  |  |  |  | 497,332,000 | 480,915,000 |  |
Research and development |  |  |  |  |  |  |  | 34,286,000 | 22,318,000 | $ 11,369,000 |
Inventories |  |  |  |  |  |  |  | 111,196,000 | 105,355,000 |  |
Raw materials |  |  |  |  |  |  |  | 62,237,000 | 67,726,000 |  |
Finished goods |  |  |  |  |  |  |  | 36,198,000 | 28,020,000 |  |
Sandoz |  |  |  |  |  |  |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairment charge |  |  |  |  |  |  |  | 0 | 0 |  |
Amortization period |  |  |  |  |  | 7 years |  |  |  |  |
Total asset purchase |  |  |  |  |  | $ 20,700,000 |  |  |  |  |
Finite-lived intangible gross carrying amount |  |  |  |  |  | 11,400,000 |  |  |  |  |
Transaction costs |  |  |  |  |  | 400,000 |  |  |  |  |
Inventories |  |  |  |  |  | 9,700,000 |  |  |  |  |
Raw materials |  |  |  |  |  | 600,000 |  |  |  |  |
Sample inventory |  |  |  |  |  | 1,000,000 |  |  |  |  |
Finished goods |  |  |  |  |  | $ 8,100,000 |  |  |  |  |
Measurement Input, Discount Rate | Sandoz |  |  |  |  |  |  |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset measurement input |  |  |  |  |  | 10 |  |  |  |  |
Oakrum Pharma |  |  |  |  |  |  |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairment charge |  |  |  |  |  |  |  | 0 |  |  |
Amortization period |  |  |  |  | 7 years |  |  |  |  |  |
Slayback Pharma Limited Liability, Company Patents and Pending Patents |  |  |  |  |  |  |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairment charge |  |  |  |  |  |  |  | 0 |  |  |
Akorn Holding Company, Pipeline Product |  |  |  |  |  |  |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairment charge |  |  |  |  |  |  |  | 0 |  |  |
Acquired ANDA intangible assets |  |  |  |  |  |  |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairment charge |  |  |  |  |  |  |  | 0 | 100,000 |  |
Finite-lived intangible gross carrying amount |  |  |  |  |  |  |  | 209,780,000 | 195,862,000 |  |
Acquired ANDA intangible assets | Oakrum Pharma |  |  |  |  |  |  |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible assets acquired |  |  |  |  | $ 7,200,000 |  |  |  |  |  |
Amortization period |  |  |  |  | 7 years |  |  |  |  |  |
Total asset purchase |  |  |  |  | $ 8,000,000 |  |  |  |  |  |
Finite-lived intangible gross carrying amount |  |  |  |  | 7,200,000 |  |  |  |  |  |
Research and development |  |  |  |  | 1,200,000 |  |  |  |  |  |
Contingent liability not recognized, asset acquisition |  |  |  |  | $ 200,000 |  |  |  |  |  |
Acquired ANDA intangible assets | Oakrum Pharma | Measurement Input, Discount Rate |  |  |  |  |  |  |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset measurement input |  |  |  |  | 13 |  |  |  |  |  |
Acquired ANDA intangible assets | Slayback Pharma Limited Liability, Company Patents and Pending Patents |  |  |  |  |  |  |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Consideration |  |  |  | $ 3,000,000.0 |  |  |  |  |  |  |
Intangible assets acquired |  |  |  | $ 2,800,000 |  |  |  |  |  |  |
Amortization period |  |  |  | 7 years |  |  |  |  |  |  |
Number of intangible assets acquired | intangibleAsset |  |  |  | 1 | 4 |  | 2 |  |  |  |
Acquired ANDA intangible assets | Akorn Holding Company, Pipeline Product |  |  |  |  |  |  |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible assets acquired |  |  |  |  |  |  | $ 4,300,000 |  |  |  |
Amortization period |  |  |  |  |  |  | 7 years |  |  |  |
Total asset purchase |  |  |  |  |  |  | $ 4,800,000 |  |  |  |
Product Intellectual Property | Alvogen Inc |  |  |  |  |  |  |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Consideration |  | $ 2,000,000 |  |  |  |  |  |  |  |  |
Intangible assets acquired |  | $ 2,000,000 |  |  |  |  |  |  |  |  |
Amortization period |  | 7 years |  |  |  |  |  |  |  |  |
Acquired pipeline product | Slayback Pharma Limited Liability, Company Patents and Pending Patents |  |  |  |  |  |  |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Number of intangible assets acquired | intangibleAsset |  |  |  |  |  |  | 1 |  |  |  |
Acquired commercial product | Slayback Pharma Limited Liability, Company Patents and Pending Patents |  |  |  |  |  |  |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Number of intangible assets acquired | intangibleAsset |  |  |  |  | 1 |  |  |  |  |  |
Acquired approved product | Slayback Pharma Limited Liability, Company Patents and Pending Patents |  |  |  |  |  |  |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Number of intangible assets acquired | intangibleAsset |  |  |  |  | 1 |  |  |  |  |  |
Acquired filed products | Slayback Pharma Limited Liability, Company Patents and Pending Patents |  |  |  |  |  |  |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Number of intangible assets acquired | intangibleAsset |  |  |  |  | 2 |  |  |  |  |  |
Acquired NDA intangible assets | Slayback Pharma Limited Liability, Company Patents and Pending Patents |  |  |  |  |  |  |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Number of intangible assets acquired | intangibleAsset |  |  |  |  |  | 3 |  |  |  |  |
Novitium |  |  |  |  |  |  |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Additional contingent consideration |  |  |  |  |  |  |  | $ 46,500,000 |  |  |
Contingent consideration period |  |  |  |  |  |  |  | 24 months |  |  |
Contingent consideration |  |  |  |  |  |  |  | $ 23,984,000 | 35,058,000 |  | $ 30,800,000
Payments on contingent consideration |  |  | $ 12,500,000 |  |  |  |  |  |  |  |
Novitium | Subsequent Event |  |  |  |  |  |  |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Payments on contingent consideration | $ 12,500,000 |  |  |  |  |  |  |  |  |  |
Interest rate swap |  |  |  |  |  |  |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Interest rate swaps, liability |  |  |  |  |  |  |  | $ 6,200,000 | $ 8,800,000 |  |

X
- Definition Business Combination, Contingent Consideration Arrangements, Period + References No definition available. + Details
Name: | anip_BusinessCombinationContingentConsiderationArrangementsPeriod
Namespace Prefix: | anip_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value of input used to measure intangible assets acquired. + References No definition available. + Details
Name: | anip_IntangibleAssetMeasurementInput
Namespace Prefix: | anip_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of Intangible Assets Acquired + References No definition available. + Details
Name: | anip_NumberOfIntangibleAssetsAcquired
Namespace Prefix: | anip_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of contingent consideration recognized as part of consideration transferred in asset acquisition. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + References No definition available. + Details
Name: | us-gaap_CashAndCashEquivalentsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1 + Details
Name: | us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsFinitelived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities. + References No definition available. + Details
Name: | us-gaap_InterestRateDerivativeLiabilitiesAtFairValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_InventoryFinishedGoods
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_InventoryNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_InventoryRawMaterials
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Gross amount of merchandise, goods, commodities, or supplies to which the entity holds the title and uses for the specific purpose of showing the benefits and features of the entity's products to existing or potential customers. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_OtherInventoryDemo
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (f) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details
Name: | us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash outflow for fees classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_PaymentsForFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireProductiveAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=anip_SandozIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=anip_OakrumPharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=anip_SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=anip_AkornHoldingCompanyPipelineProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_ProductIntellectualPropertyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=anip_AlvogenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredPipelineProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredCommercialProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredApprovedProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredFiledProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredNDAIntangibleAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |